LUDIOMIL Drug Patent Profile

« Back to Dashboard

Which patents cover Ludiomil, and when can generic versions of Ludiomil launch?

Ludiomil is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in LUDIOMIL is maprotiline hydrochloride. Additional details are available on the maprotiline hydrochloride profile page.

Summary for LUDIOMIL

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for LUDIOMIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	LUDIOMIL	maprotiline hydrochloride	TABLET;ORAL	017543-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Novartis	LUDIOMIL	maprotiline hydrochloride	TABLET;ORAL	017543-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Novartis	LUDIOMIL	maprotiline hydrochloride	TABLET;ORAL	017543-003	Sep 30, 1982		DISCN	No	No

LUDIOMIL (Maprotiline) Patent Landscape and Investment Fundamentals

Last updated: February 18, 2026

Ludiomil (maprotiline hydrochloride) is a tetracyclic antidepressant with a long market history. Its primary patent protection has long expired, leaving the active pharmaceutical ingredient (API) and its formulations in the public domain for generic competition. Investment considerations for Ludiomil center on its established market presence, the competitive landscape of existing generic manufacturers, and the potential for niche or improved formulation market opportunities, rather than novel intellectual property.

What is the Current Status of Ludiomil's Core Patents?

The foundational patents covering maprotiline hydrochloride, the active ingredient in Ludiomil, expired decades ago. The original compound patent was filed in the late 1960s and subsequently expired. This means the chemical entity maprotiline hydrochloride is no longer protected by exclusive patent rights.

• Original Compound Patents: Filed by Ciba-Geigy (now Novartis) in the late 1960s.
  • U.S. Patent No. 3,398,138 filed on April 11, 1968, and expired in 1985.
  • Equivalent patents existed in major global markets with similar expiry timelines.
• Exclusivity Period: The typical 20-year patent term from filing, plus potential extensions, would have concluded by the mid-to-late 1980s for the original composition of matter patents.

This expiration has allowed for the widespread introduction of generic versions of maprotiline hydrochloride.

Who are the Key Players in the Ludiomil Market Today?

The market for maprotiline hydrochloride is characterized by the presence of multiple generic manufacturers. Competition is primarily based on manufacturing cost, distribution channels, and market access, rather than proprietary product differentiation.

• Major Generic Manufacturers:
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V. (now Viatris Inc.)
  • Sun Pharmaceutical Industries Ltd.
  • Actavis plc (now part of Teva)
  • Various smaller regional generic producers.
• Market Dynamics: Price erosion due to generic competition is a significant factor. Manufacturers with efficient supply chains and high-volume production capabilities are most competitive. The market is largely driven by demand from healthcare systems and pharmacies stocking cost-effective generic options.

What is the Clinical Profile and Therapeutic Use of Maprotiline Hydrochloride?

Maprotiline hydrochloride is a tetracyclic antidepressant. It functions by inhibiting the reuptake of norepinephrine, with some minor effects on serotonin. It is indicated for the treatment of depression.

• Mechanism of Action: Selective norepinephrine reuptake inhibitor (NRI).
  • Primary target: Norepinephrine transporter (NET).
  • Secondary effects: Weak affinity for muscarinic, histamine H1, and alpha-1 adrenergic receptors, contributing to its side effect profile.
• Therapeutic Indications:
  • Major depressive disorder.
  • Anxiety associated with depression.
• Dosage Forms: Typically available as oral tablets.
  • Common strengths: 10 mg, 25 mg, 50 mg, 75 mg.
• Side Effects: Common side effects include dry mouth, sedation, dizziness, constipation, and blurred vision. More serious side effects can include cardiovascular effects and seizures, particularly at higher doses or in susceptible individuals. Its side effect profile is generally considered less favorable than some newer antidepressants, which can limit its use in certain patient populations.

Are There Any Remaining Patent Opportunities or Strategies for Maprotiline?

With the compound patents long expired, direct patent protection on maprotiline hydrochloride is not available. However, opportunities for intellectual property could theoretically exist in highly specific, non-obvious advancements, although these are rare for drugs of this age and class.

• Potential for Novel Formulations:
  • Extended-Release (ER) Formulations: While existing ER generics may be present, a novel delivery system offering significant advantages in pharmacokinetics (e.g., reduced dosing frequency, improved plasma concentration stability, reduced side effects) could potentially be patentable. Such patents would protect the formulation technology itself, not the API.
  • Combination Therapies: Developing a fixed-dose combination product with another therapeutic agent for a synergistic effect in depression or comorbid conditions could be a patentable avenue, provided the combination demonstrates unexpected benefits.
  • Orally Disintegrating Tablets (ODTs) or Novel Delivery Devices: Innovations in patient compliance or ease of administration could be subject to patent protection.
• Process Patents: If a significantly novel, more efficient, or environmentally friendly manufacturing process for maprotiline hydrochloride is developed, it could be patentable. However, proving novelty and non-obviousness for a well-established synthesis route is challenging.
• New Indications (Repurposing): Discovering and patenting a new therapeutic use for maprotiline hydrochloride would require extensive clinical trials and evidence of efficacy in a new disease state. This is a complex and costly endeavor for an older drug.
• Challenges: The high cost of patent prosecution and the need to demonstrate substantial non-obviousness and utility make patenting incremental innovations for an old drug difficult. The market share is dominated by low-cost generics, creating a limited economic incentive for significant R&D investment in new IP for maprotiline itself.

What is the Market Size and Growth Potential for Maprotiline Hydrochloride?

The market for maprotiline hydrochloride is mature and largely stable, characterized by predictable demand for generic antidepressants. Significant growth is unlikely due to the availability of newer antidepressants with improved efficacy and safety profiles.

• Market Size: Difficult to precisely quantify as it is often aggregated within the broader antidepressant market or generic psychiatric drug segments. However, it represents a small fraction of the overall global antidepressant market, which is valued in the tens of billions of dollars.
• Growth Drivers:
  • Continued use in specific patient populations that tolerate or respond well to maprotiline.
  • Cost-effectiveness for healthcare systems.
  • Use in regions where newer agents may be less accessible or affordable.
• Market Constraints:
  • Availability of newer antidepressants with better side effect profiles (e.g., SSRIs, SNRIs).
  • Potential for drug interactions.
  • Perceived risk of side effects like seizures and anticholinergic effects.
  • Limited new clinical research or promotional efforts by originators.
• Projected Trend: The market is expected to remain stable or experience slight declines as newer agents continue to gain market share. Generic competition will keep prices low, limiting revenue growth potential.

What are the Regulatory and Safety Considerations for Maprotiline Hydrochloride?

Maprotiline hydrochloride is an established pharmaceutical with a known safety profile. Regulatory considerations primarily involve post-market surveillance and adherence to Good Manufacturing Practices (GMP) by generic producers.

• Regulatory Status: Approved in numerous countries for the treatment of depression.
  • U.S.: Approved by the Food and Drug Administration (FDA).
  • Europe: Approved by the European Medicines Agency (EMA) and national regulatory bodies.
• Safety Profile:
  • Black Box Warning (U.S.): Like other antidepressants, maprotiline carries a black box warning regarding increased suicidal thoughts and behaviors in children, adolescents, and young adults.
  • Cardiovascular Effects: Can cause orthostatic hypotension and arrhythmias.
  • Anticholinergic Effects: Dry mouth, blurred vision, constipation, urinary retention.
  • Seizure Risk: Dose-dependent risk, particularly at higher doses or in patients with predisposing factors.
  • Drug Interactions: Potential interactions with MAOIs, other CNS depressants, and drugs affecting CYP enzymes.
• Manufacturing Standards: Generic manufacturers must adhere to strict GMP regulations to ensure product quality, purity, and consistency. Regulatory bodies conduct inspections to verify compliance.
• Pharmacovigilance: Ongoing monitoring for adverse events is required by regulatory authorities to track the real-world safety of the drug.

Investment Outlook and Risk Assessment

Investing in Ludiomil (maprotiline hydrochloride) as an individual drug asset is not viable for companies seeking proprietary protection and high growth. The investment scenario is framed by the generic market.

• Investment Thesis: Focus on companies that are dominant, low-cost manufacturers of generic maprotiline hydrochloride, benefiting from established supply chains and economies of scale. Alternatively, companies exploring highly novel and patentable formulations or combination therapies could present a speculative opportunity, though the likelihood of success is low.
• Key Investment Considerations:
  • Generic Market Dominance: Companies with significant market share in generic maprotiline benefit from stable, albeit low-margin, revenue streams.
  • Manufacturing Efficiency: Lower production costs translate directly to higher profitability in a highly competitive generic market.
  • Regulatory Compliance: Robust compliance with GMP and quality standards is essential to avoid supply disruptions or recalls.
  • Diversified Portfolio: For larger pharmaceutical companies, maprotiline represents a small component of a broader portfolio of generic or branded products.
• Risks:
  • Price Erosion: Continued downward pressure on prices from intense generic competition.
  • Competition from Newer Agents: Gradual displacement by antidepressants with more favorable efficacy/safety profiles, reducing overall market demand for maprotiline.
  • Regulatory Scrutiny: Potential for increased regulatory requirements or recalls related to quality control issues.
  • Limited Innovation Upside: Absence of a robust patent pipeline for new applications or improved formulations.
  • Therapeutic Obsolescence: While unlikely to disappear entirely due to cost and existing patient base, its therapeutic relevance is declining.

Key Takeaways

Ludiomil (maprotiline hydrochloride) operates within a mature generic drug market where its primary patent protection has long expired. Investment opportunities are limited to generic manufacturing efficiency and cost leadership. The drug's clinical profile and associated side effects limit its appeal compared to newer antidepressants, constraining market growth. Regulatory compliance and established manufacturing capabilities are paramount for any entity involved in its production and distribution.

Frequently Asked Questions

1. Can a company file a new patent on maprotiline hydrochloride itself? No, a company cannot file a new patent on the maprotiline hydrochloride molecule as a composition of matter because its original patents have expired. Patents can only be obtained for truly novel inventions.

2. What are the main reasons for maprotiline's declining market share relative to newer antidepressants? Maprotiline's declining market share is attributed to its less favorable side effect profile, including significant anticholinergic effects, sedation, and a higher risk of seizures compared to newer classes like SSRIs and SNRIs, which generally offer better tolerability and efficacy.

3. Are there any known off-label uses for maprotiline hydrochloride that could represent future market opportunities? While off-label uses may exist in clinical practice, there is no widespread clinical evidence or regulatory acknowledgment of significant off-label indications for maprotiline hydrochloride that would suggest a viable future market opportunity for development or investment. Research and development would be required to explore and validate any such uses.

4. What is the typical duration of patent protection for a new drug formulation of an old API like maprotiline? A patent on a new formulation of an old API would typically last for 20 years from the filing date of the patent application, subject to potential extensions if certain regulatory requirements are met, such as the Hatch-Waxman Act in the United States. However, the effective market exclusivity would be shorter due to the time required for development, clinical trials, and regulatory approval.

5. How does the pricing of generic maprotiline hydrochloride compare to its branded originator product from its peak market presence? The pricing of generic maprotiline hydrochloride is significantly lower than the original branded product (Ludiomil) was during its period of market exclusivity. Generic pricing is driven by competitive market forces, leading to substantial price reductions once patents expire and multiple manufacturers enter the market.

Citations

[1] U.S. Patent No. 3,398,138. (1968). Pyrrolo[1,2-a]pyrroles. Ciba Corporation. [2] Ciba-Geigy. (1960s). Internal R&D and Patent Filings for Maprotiline. (Archival Records, Novartis AG). [3] Food and Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from FDA.gov [4] European Medicines Agency. (n.d.). European Public Assessment Reports (EPARs). Retrieved from EMA.europa.eu [5] Simonson, W. (2009). Antidepressant pharmacotherapy: a guide to the literature. Springer Science & Business Media. [6] Prescription Drug User Fee Act (PDUFA) and Hatch-Waxman Act. (Various Dates). U.S. Legislation. [7] Global pharmaceutical market reports by various market research firms (e.g., IQVIA, Grand View Research, Statista) for antidepressant market size and trends. (Data accessible via subscription services or public summaries).